Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBIT (2016 - 2025)

Historic EBIT for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' EBIT rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$11.5 million for FY2024, which is 8957.83% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' EBIT is -$4.1 million, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBIT registered a high of $4.2 million during Q4 2024, and its lowest value of -$62.9 million during Q1 2022.
  • Moreover, its 5-year median value for EBIT was -$24.9 million (2023), whereas its average is -$27.2 million.
  • As far as peak fluctuations go, Heron Therapeutics' EBIT crashed by 2074.11% in 2022, and later soared by 16573.57% in 2025.
  • Quarter analysis of 5 years shows Heron Therapeutics' EBIT stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then tumbled by 198.08% to -$4.1 million in 2025.
  • Its EBIT was -$4.1 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.2 million in Q1 2025.